Abstract

Fusion genes are hallmarks of various cancer types and important determinants for diagnosis, prognosis and treatment. Fusion gene partner choice and breakpoint-position promiscuity restricts diagnostic detection, even for known and recurrent configurations. Here, we develop FUDGE (FUsion Detection from Gene Enrichment) to accurately and impartially identify fusions. FUDGE couples target-selected and strand-specific CRISPR-Cas9 activity for fusion gene driver enrichment — without prior knowledge of fusion partner or breakpoint-location — to long read nanopore sequencing with the bioinformatics pipeline NanoFG. FUDGE has flexible target-loci choices and enables multiplexed enrichment for simultaneous analysis of several genes in multiple samples in one sequencing run. We observe on-average 665 fold breakpoint-site enrichment and identify nucleotide resolution fusion breakpoints within 2 days. The assay identifies cancer cell line and tumor sample fusions irrespective of partner gene or breakpoint-position. FUDGE is a rapid and versatile fusion detection assay for diagnostic pan-cancer fusion detection.

Fusion genes are a hallmarks of cancer, though breakpoint-position promiscuity restricts diagnostic detection. Here, the authors present FUDGE, a CRISPR-Cas9-based enrichment strategy for nanopore sequencing to identify target fusions irrespective of genomic breakpoint or fusion partner.

Details

Title
Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing
Author
Stangl, Christina 1 ; de Blank Sam 2   VIAFID ORCID Logo  ; Renkens Ivo 2 ; Westera Liset 3 ; Verbeek, Tamara 2 ; Valle-Inclan Jose Espejo 4 ; González, Rocio Chamorro 5   VIAFID ORCID Logo  ; Henssen, Anton G 6   VIAFID ORCID Logo  ; van Roosmalen Markus J 7 ; Stam, Ronald W 8 ; Voest, Emile E 9   VIAFID ORCID Logo  ; Kloosterman Wigard P 2   VIAFID ORCID Logo  ; van Haaften Gijs 2   VIAFID ORCID Logo  ; Monroe, Glen R 2   VIAFID ORCID Logo 

 University Medical Center Utrecht and Utrecht University, Department of Genetics, Center for Molecular Medicine, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Plesmanlaan, Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands (GRID:grid.7692.a); Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d) 
 University Medical Center Utrecht and Utrecht University, Department of Genetics, Center for Molecular Medicine, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352) 
 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (GRID:grid.487647.e); Dutch Childhood Oncology Group (DCOG), Den Haag, Netherlands (GRID:grid.476268.9) (ISNI:0000 0004 0395 3851) 
 University Medical Center Utrecht and Utrecht University, Department of Genetics, Center for Molecular Medicine, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d) 
 Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849) 
 Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849); German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Berlin Institute of Health, Berlin, Germany (GRID:grid.484013.a) 
 Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d); Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (GRID:grid.487647.e) 
 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (GRID:grid.487647.e) 
 Plesmanlaan, Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands (GRID:grid.487647.e); Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2409865621
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.